Is Metformin Used to Treat Myotonic Dystrophy?

Metformin is not currently approved as a standard treatment for myotonic dystrophy, but it is actively being researched in clinical trials as a potential therapy. It belongs to a category of medications known as “repurposed drugs,” which are already approved for other conditions (like type 2 diabetes) but are now being studied to see if they can help manage symptoms of myotonic dystrophy type 1 (DM1) ^[1]. Alongside metformin, which is being investigated for its effects on walking and mobility, researchers are also exploring drugs like pitolisant (a narcolepsy medication) to help manage excessive daytime sleepiness. While early research on some of these drugs is promising, patients should always consult their neurologist about the current medical evidence before seeking off-label prescriptions.

The Promise of Repurposed Drugs

Drug repurposing involves taking a medication that is already proven safe for one disease and testing it for another ^[1][2]. In myotonic dystrophy, researchers are testing several existing small-molecule drugs. Some new drugs aim to fix the root cause of the disease by reducing “toxic RNA” (a buildup of faulty genetic material that causes the disease) ^[2][3]. However, repurposed drugs like metformin and pitolisant do not fix this genetic root cause; instead, they are used to manage downstream daily symptoms. Because the safety profiles of these drugs are already well understood, repurposed drugs can sometimes reach clinical use faster than entirely new experimental therapies.

Metformin: Investigating Mobility and Gait

Metformin is widely known as a treatment for type 2 diabetes, but scientists believe it may also help with the metabolic and age-related changes seen in DM1 ^[4]. Specifically, researchers hope it might improve muscle function and walking ability ^[5][6].

A Phase 2 clinical trial involving patients with DM1 tested whether metformin could improve physical abilities. The results showed that a specific group of patients who took the maximum tolerated dose of metformin had a significant improvement in the distance they could walk in six minutes compared to those taking a placebo. They also demonstrated better total mechanical power during walking, meaning they had a smoother and more efficient walking stride ^[7].

However, the drug did not show significant improvements in overall muscle strength or the delayed muscle relaxation (myotonia) characteristic of the disease. It is also important to note that patients taking metformin experienced a higher rate of mild to moderate gastrointestinal side effects, such as diarrhea and stomach discomfort ^[7]. Larger Phase 3 trials are necessary to fully confirm its benefits and safety for DM1.

Pitolisant: Targeting Excessive Daytime Sleepiness

Beyond physical mobility, profound fatigue and excessive daytime sleepiness are major challenges for many people living with myotonic dystrophy. Pitolisant is a medication currently approved to treat daytime sleepiness in conditions like narcolepsy ^[8][9]. It works by interacting with receptors in the brain to increase the release of histamine, a chemical that promotes wakefulness ^[8][10].

Due to its success in other sleep disorders, it has gained attention in patient forums as a potential repurposed treatment for sleepiness in DM1. However, unlike metformin, there is currently very limited evidence and no human clinical trial data proving its effectiveness specifically for myotonic dystrophy ^[11]. In fact, one animal model study of the disease showed no behavioral improvements with the drug ^[11]. Furthermore, pitolisant is not without risks; its most common side effects include headache, insomnia, nausea, and anxiety ^[12][13]. Rigorous clinical testing is required before it can be considered a safe and effective option for DM1 patients.

Navigating Off-Label Prescriptions

Because drugs like metformin and pitolisant are already available at pharmacies, it can be tempting to ask a doctor to prescribe them “off-label” (using an approved drug for an unapproved purpose). While some doctors may consider this based on your specific symptom profile, it is crucial to approach this cautiously. Current standard care for DM1 emphasizes managing specific multisystem symptoms—including heart issues, sleep disorders, and muscle impairment—rather than relying on unproven therapies ^[14][15]. Always discuss the most current clinical trial evidence with your neurologist to determine the safest and most effective management plan for your unique symptoms, and ask if there are active clinical trials (often found on ClinicalTrials.gov) that you might be eligible to join.